Circulating microRNAs as clinically useful biomarkers for Type 2 Diabetes Mellitus: miRNomics from bench to bedside

Grieco, Giuseppina Emanuela; Besharat, Zein Mersini; Licata, Giada; Fignani, Daniela; Brusco, Noemi; Nigi, Laura; Formichi, Caterina; Pò, Agnese; Sabato, Claudia; Dardano, Angela; Natali, Andrea; Dotta, Francesco; Sebastiani, Guido; Ferretti, Elisabetta

doi:10.1016/j.trsl.2022.03.008

Cited by 17 publications

(18 citation statements)

References 96 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This epigenetic alteration includes non-coding RNA, such as miRNA modifications [ 26 ]. In this line, circulating miRNAs [ 27 , 28 , 29 ] have emerged in recent years as potential diagnostic and prognostic biomarkers for many diseases, including both GDM [ 30 ] and T2D [ 8 ]. Among the different miRNAs related to T2D [ 31 , 32 ], we have selected hsa-miR-24-3p, hsa-miR-543-3p, hsa-miR-329-3p, and hsa-miR-1-3p.…”

Section: Discussionmentioning

confidence: 99%

“…By contrast, hsa-miR-24-3p has not been deeply studied in the development of T2D, and only a few authors have related circulating levels of hsa-miR-24-3p with the diagnosis of diabetes. In addition, while some authors find lower levels of this miRNA in diabetic patients compared to controls [ 8 , 15 , 30 ], other studies state that metformin treatment and improvement in glycemic status in T2D patients are directly associated with decreased levels of hsa-miR-24-3p [ 33 ], it is important to note that those works in which the levels of hsa-miR-24-3p were reduced in patients with T2D, the patients were treated with different hypoglycemic drugs, so, as has already been shown with metformin, not only glucose and HbA1c levels could be affected, but also the expression levels of hsa-miR-24-3p.…”

Section: Discussionmentioning

confidence: 99%

“…There is increasing evidence that epigenetic processes, including non-coding RNAs, play a role in the development of metabolic diseases [ 7 ]. Numerous studies have proposed the use of circulating microRNAs (c-miRNAs) as diagnostic, prognostic, and therapeutic biomarkers of diverse pathological processes, including metabolic diseases [ 8 , 9 , 10 ]. In the last years, a considerable amount of information has been published describing the association of GDM with the expression of certain miRNAs detected in plasma and different tissues, as we have recently reviewed [ 11 ].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

miR-24-3p and Body Mass Index as Type 2 Diabetes Risk Factors in Spanish Women 15 Years after Gestational Diabetes Mellitus Diagnosis

Blanco

Lambert

Fernández-Sanjurjo

et al. 2023

IJMS

View full text Add to dashboard Cite

Gestational diabetes mellitus (GDM) is defined as any degree of glucose intolerance that is diagnosed for the first time during pregnancy. The objective of this study is to know the glucose tolerance status after 15 years of pregnancy in patients diagnosed with gestational diabetes and to assess the long-term effect of GDM on the circulating miRNA profile of these women. To answer these, 30 randomly selected women diagnosed with GDM during 2005–2006 were included in the study, and glucose tolerance was measured using the National Diabetes Data Group criteria. Additionally, four miRNAs (hsa-miR-1-3p, hsa-miR-24-3p, hsa-miR-329-3p, hsa-miR-543) were selected for their analysis in the plasma of women 15 years after the diagnosis of GDM. In our study we discovered that, fifteen years after the diagnosis of GDM, 50% of women have some degree of glucose intolerance directly related to body weight and body mass index during pregnancy. Dysglycemic women also showed a significantly increased level of circulating hsa-miR-24-3p. Thus, we can conclude that initial weight and BMI, together with circulating expression levels of hsa-miR-24-3p, could be good predictors of the future development of dysglycemia in women with a previous diagnosis of GDM.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

miR-24-3p and Body Mass Index as Type 2 Diabetes Risk Factors in Spanish Women 15 Years after Gestational Diabetes Mellitus Diagnosis

Blanco

Lambert

Fernández-Sanjurjo

et al. 2023

IJMS

View full text Add to dashboard Cite

show abstract

“…Additionally, growing evidence has also shown that miR‐34a‐5p exert crucial functions in various diseases. miR‐34a‐5p has been implicated in diabetes as a clinically useful biomarker or as a target to regulate pancreatic β‐cell proliferation (Grieco et al, 2022; Lu et al, 2016; Su et al, 2021). Thus, ATM as a metabolism‐regulated agent may have potential role in some diseases such as diabetes through a miR‐34a‐5p‐mediated pathway, but further studies are needed to clarify this area.…”

Section: Discussionmentioning

confidence: 99%

Therapeutic role of Artemether in the prevention of hepatic steatosis through miR‐34a‐5p/PPARα pathway

Chen

Hong

et al. 2022

Drug Development Research

View full text Add to dashboard Cite

Artemether (ATM) is a natural antimalarial drug that can also regulate glucose and lipid metabolism. However, little is known regarding its pharmacological action in metabolic dysfunction-associated fatty liver disease (MAFLD), and the underlying mechanisms remain undetermined. The aim of this study was to explore the therapeutic effects of ATM against hepatic steatosis and the possible mechanisms. ATM significantly decreased blood glucose levels, improved glucose tolerance, reduced inflammatory response, and alleviated hepatic steatosis in the ob/ob mouse model as well as the high-fat diet-fed mice. ATM also inhibited lipid accumulation in murine hepatocytes in vitro.Using RNA sequencing, miR-34a-5p and peroxisome proliferator-activated receptor-α (PPARα) were identified as important regulators during ATM treatment. ATM administration downregulated miR-34a-5p expression and miR-34a-5p abrogated the inhibitory effects of ATM on PO (palmitate + oleate)induced lipid accumulation as well as triglycerides levels in murine hepatocytes.Furthermore, the expression of PPARα, a target gene of miR-34a-5p, was upregulated by ATM and PPARα inhibitor MK-886 abolished the positive effect of ATM. Consequently, PPARα agonist fenofibrate reversed the decreased mitochondrial fatty acid β-oxidation induced by miR-34a-5p mimics after ATM treatment, thereby leading to attenuation of intracellular lipid accumulation. Taken together, ATM is a promising therapeutic agent against MAFLD that reduces lipid deposition by suppressing miR-34a-5p and upregulating PPARα.

show abstract

“…MiRNAs can act as oncogenes or tumor suppressors, influencing many aspects of cancer biology such as proliferation, differentiation, angiogenesis, and metastasis [20,21]. Moreover, some studies have demonstrated that miRNAs are released into the circulation and that the circulating miRNAs are altered during various pathologic conditions, such as inflammation, infection, metabolic disorders, and sepsis [22][23][24].…”

Section: Introductionmentioning

confidence: 99%

Regulation of VEGFA, KRAS, and NFE2L2 Oncogenes by MicroRNAs in Head and Neck Cancer

Cuzziol

Marzochi

Possebon

et al. 2022

IJMS

View full text Add to dashboard Cite

Mutations and alterations in the expression of VEGFA, KRAS, and NFE2L2 oncogenes play a key role in cancer initiation and progression. These genes are enrolled not only in cell proliferation control, but also in angiogenesis, drug resistance, metastasis, and survival of tumor cells. MicroRNAs (miRNAs) are small, non-coding regulatory RNA molecules that can regulate post-transcriptional expression of multiple target genes. We aimed to investigate if miRNAs hsa-miR-17-5p, hsa-miR-140-5p, and hsa-miR-874-3p could interfere in VEGFA, KRAS, and NFE2L2 expression in cell lines derived from head and neck cancer (HNC). FADU (pharyngeal cancer) and HN13 (oral cavity cancer) cell lines were transfected with miR-17-5p, miR-140-5p, and miR-874-3p microRNA mimics. RNA and protein expression analyses revealed that miR-17-5p, miR-140-5p and miR-874-3p overexpression led to a downregulation of VEGFA, KRAS, and NFE2L2 gene expression in both cell lines analyzed. Taken together, our results provide evidence for the establishment of new biomarkers in the diagnosis and treatment of HNC.

show abstract

Circulating microRNAs as clinically useful biomarkers for Type 2 Diabetes Mellitus: miRNomics from bench to bedside

Cited by 17 publications

References 96 publications

miR-24-3p and Body Mass Index as Type 2 Diabetes Risk Factors in Spanish Women 15 Years after Gestational Diabetes Mellitus Diagnosis

miR-24-3p and Body Mass Index as Type 2 Diabetes Risk Factors in Spanish Women 15 Years after Gestational Diabetes Mellitus Diagnosis

Therapeutic role of Artemether in the prevention of hepatic steatosis through miR‐34a‐5p/PPARα pathway

Regulation of VEGFA, KRAS, and NFE2L2 Oncogenes by MicroRNAs in Head and Neck Cancer

Contact Info

Product

Resources

About